A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study

Gynecologic Oncology

Volumn 122, Issue 1, 2011, Pages 111-115

  Coleman, Robert L ^a   Brady, William E ^b   McMeekin, D Scott ^c   Rose, Peter G ^d   Soper, John T ^e   Lentz, Samuel S ^f   Hoffman, James S ^g   Shahin, Mark S ^h  

^a UNIVERSITY OF TEXAS   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g NEW BRITAIN GENERAL HOSPITAL   (United States)

^h ABINGTON MEMORIAL HOSPITAL   (United States)

Author keywords

Fallopian tube cancer; Nab paclitaxel; Ovarian cancer; Platinum resistant; Primary peritoneal cancer; Taxane resistant

Indexed keywords

ADRENALIN; ALBUMIN; BEVACIZUMAB; CARBOPLATIN; NANOPARTICLE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; STEROID;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; METABOLIC DISORDER; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PAIN; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THERAPY RESISTANCE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA;

ADULT; AGED; ALBUMINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG RESISTANCE, NEOPLASM; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NANOPARTICLES; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS;

EID: 79957759352     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.03.036     Document Type: Article

References (38)

1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. [comment]. New Eng J Med 1996;334:1-6. (Pubitemid 26012496)
2. Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinumresistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol 2009;27:2686-91.
3. 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 2006;101:436-40.
4. Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003;88:130-5. (Pubitemid 36263370)
5. Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 2008;60:876-85.
6. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006;7:1041-53. (Pubitemid 43949942)
7. Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 2008;14:4200-5.
8. Desai NP, Trieu V, Hwang LY, Wu R, Soon-Shiong P, Gradishar WJ. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbatebased docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008;19:899-909.
9. Henderson IC, Bhatia V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther 2007;7:919-43. (Pubitemid 47180894)
10. Dranitsaris G, Coleman R, Gradishar W. Nab-paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. Breast Cancer Res Treat 2010;119:717-24.
11. John TA, Vogel SM, Minshall RD, Ridge K, Tiruppathi C, Malik AB. Evidence for the role of alveolar epithelial gp60 in active transalveolar albumin transport in the rat lung. J Physiol 2001;533:547-59. (Pubitemid 32520007)
12. Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol 2009;2:59-64.
13. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor- free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317-24. (Pubitemid 43342524)
14. Teneriello MG, Tseng PC, Crozier M, Encarnacion C, Hancock K, Messing MJ, et al. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinumsensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol 2009;27:1426-31.
15. Benigno BB, Burrell MO, Daugherty P, Hernandez P. A phase II nonrandomized study of nab-paclitaxel plus carboplatin in patients with recurrent platinumsensitive ovarian or primary peritoneal cancer. J Clin Oncol 2010;28 Abstr 5011.
16. Boruta 2nd DM, Fowler Jr WC, Gehrig PA, Boggess JF, Walton LA, Van Le L. Weekly paclitaxel infusion as salvage therapy in ovarian cancer. Cancer Invest 2003;21:675-81.
17. Ghamande S, Lele S, Marchetti D, Baker T, Odunsi K. Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer. Int J Gynecol Cancer 2003;13:142-7. (Pubitemid 37055468)
18. Kita T, Kikuchi Y, Takano M, Suzuki M, Oowada M, Konno R, et al. The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer. Gynecol Oncol 2004;92:813-8. (Pubitemid 38251382)
19. Markman M. Weekly paclitaxel in the management of ovarian cancer. Semin Oncol 2000;27:37-40. (Pubitemid 30643851)
20. Markman M, Hall J, Spitz D, Weiner S, Carson L, Van Le L, et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 2002;20:2365-9. (Pubitemid 34441665)
21. Thomas H, Rosenberg P. Role of weekly paclitaxel in the treatment of advanced ovarian cancer. Crit Rev Oncol Hematol 2002;44(Suppl):S43-51.
22. Rose PG, Tian C, Bookman MA. Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2010;117:324-9.
23. Byrd L, Thistlethwaite FC, Clamp A, Ton C, Hasan J, Jayson GC. Weekly paclitaxel in the treatment of recurrent ovarian carcinoma. Eur J Gynaecol Oncol 2007;28:174-8. (Pubitemid 46985636)
24. Kaern J, Baekelandt M, Trope CG. A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients. Eur J Gynaecol Oncol 2002;23:383-9. (Pubitemid 35364663)
25. Albertsson P, Lennernas B, Norrby K. On metronomic chemotherapy: modulation of angiogenesis mediated by VEGE-A. Acta Oncol 2006;45:144-55.
26. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843-9. (Pubitemid 26384151)
27. Chen CA, Ho CM, Chang MC, Sun WZ, Chen YL, Chiang YC, et al. Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol Ther 2010;18:1233-43.
28. Damber JE, Vallbo C, Albertsson P, Lennernas B, Norrby K. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol 2006;58:354-60. (Pubitemid 43800739)
29. Drevs J, Fakler J, Eisele S, Medinger M, Bing G, Esser N, et al. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 2004;24:1759-63. (Pubitemid 38954706)
30. Hata K, Osaki M, Dhar DK, Nakayama K, Fujiwaki R, Ito H, et al. Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line. Cancer Chemother Pharmacol 2004;53:68-74. (Pubitemid 38161191)
31. Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 2005;11:6966-71. (Pubitemid 41428755)
32. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997;57:81-6. (Pubitemid 27021522)
33. Lau DH, Xue L, Young LJ, Burke PA, Cheung AT. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 1999;14:31-6. (Pubitemid 29157732)
34. Pasquier E, Honore S, Pourroy B, Jordan MA, Lehmann M, Briand C, et al. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 2005;65:2433-40. (Pubitemid 40490155)
35. Wang J, Lou P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 2003;14:13-9. (Pubitemid 36177350)
36. Lau D, Guo L, Gandara D, Young LJ, Xue L. Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent? Anticancer Drugs 2004;15:871-5.
37. Kamat AA, Kim TJ, Landen Jr CN, Lu C, Han LY, Lin YG, et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 2007;67:281-8. (Pubitemid 46142786)
38. Hurt JD, Richardson DL, Seamon LG, Fowler JF, Copeland LJ, Cohn DE, et al. Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. Gynecol Oncol 2009;115:396-400.